Moreover, previous results have demonstrated that DNMT1 acts as a promoter of lung cancer, and the safety and feasibility of CRISPR/Cas9 gene-editing approaches in NSCLC have been verified (Lu et al., 2020). Here, DNMT1 is linked to non-small cell lung carcinoma.